Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 11;15(3):345. doi: 10.3390/ph15030345

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The changes from the baseline of the levels (mean ± SEM) of (a) creatinine and (b) C-reactive protein in the blood of patients in group A (ADAPT-232) and group B (placebo) over the time from Day 1 to Day 21. Between-groups comparison of the creatinine shows a significant difference (p = 0.0012) between groups A and B. The ADAPT-232 treatment significantly decreased blood creatinine compared to placebo. For details of statistical analysis, see Supplement 2. Between-groups comparison of the changes of C-reactive protein in blood from the baseline over time shows no interaction (p = 0.7100) and no significant difference (p = 0.1276) between groups A and B. The ADAPT-232 treatment has no statistically significant effect on C-reactive protein level in blood compared to placebo. *—p < 0.05 and **—p< 0.01. For details of statistical analysis, see Supplement 2.